If you or a loved one has been taking Reglan and noticed involuntary movements, you may be worried about tardive dyskinesia. The diagnostic process involves specific clinical assessments to confirm the condition. Drawing from decades of medical research on medication-induced movement disorders, this page explains how healthcare providers evaluate and diagnose this serious side effect.
Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. The FDA-approved labeling states that Reglan tablets are indicated for treatment lasting 4 to 12 weeks for gastroesophageal reflux and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the same labeling includes a boxed warning that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The prescribing information describes TD as a syndrome of potentially irreversible and disfiguring movements that may be suppressed or partially suppressed by metoclopramide, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves dopamine receptor blockade in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent abnormal motor control. This effect is dose-dependent and cumulative, with longer exposure increasing the likelihood of permanent neurological damage. The adequacy of warnings regarding Reglan and TD is a central issue in litigation. The boxed warning explicitly states that Reglan is contraindicated in patients with a history of TD and that the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the labeling advises avoiding treatment longer than 12 weeks, and if longer use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, many patients were prescribed Reglan for extended periods, sometimes years, without adequate monitoring or informed consent about TD risks.
Settlement-related considerations for affected patients include the statute of limitations, which varies by state. In Pennsylvania, the statute of limitations for personal injury claims, including those related to prescription drug injuries, is generally two years from the date the injury was discovered or reasonably should have been discovered. For TD, the timeline between exposure and documented harm can be critical. TD may develop months or years after starting Reglan, and symptoms can persist or worsen even after discontinuation. The boxed warning notes that metoclopramide may suppress or partially suppress signs of TD, potentially delaying recognition of the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This delay can complicate the determination of when the statute of limitations begins to run. Patients who developed TD after using Reglan may be eligible for compensation through settlements or verdicts. Key factors in such cases include the duration of Reglan use, the presence of adequate warnings, and the timing of diagnosis. The FDA labeling emphasizes that Reglan has not been shown to be safe and effective for gastroesophageal reflux beyond 12 weeks, and it is not recommended for pediatric patients due to TD risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If a patient was prescribed Reglan for longer than recommended or without proper monitoring, this may strengthen a claim. The risk narrative for Pennsylvania patients involves understanding the state's specific legal deadlines. The two-year statute of limitations typically starts when the patient knew or should have known that Reglan caused their TD. Given that TD can be subtle initially and may be misattributed to other causes, the discovery date can be disputed. Medical records documenting the onset of involuntary movements and the patient's history of Reglan use are essential evidence. Additionally, the cumulative dosage and duration of treatment are directly linked to risk, as stated in the boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In summary, Reglan-associated TD is a serious, potentially irreversible condition with a clear dose-response relationship. The FDA-mandated warnings advise short-term use and monitoring, but many patients were exposed beyond these limits. For Pennsylvania residents, the statute of limitations requires prompt action after discovery of harm. Legal evaluation should consider the timeline of Reglan use, the onset of TD symptoms, and the adequacy of warnings provided by prescribers and manufacturers.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Pennsylvania, the statute of limitations for personal injury claims, including those related to prescription drug injuries, is generally two years from the date the injury was discovered or reasonably should have been discovered. For tardive dyskinesia caused by Reglan, this means the clock starts when the patient knew or should have known that Reglan caused their condition. Given that TD symptoms can be subtle and may be suppressed by the drug, the discovery date can be complex and may require medical documentation.
Key evidence includes medical records documenting the duration and dosage of Reglan use, the onset and progression of involuntary movements, and any diagnoses of tardive dyskinesia. Also important are records showing that the prescribing physician did not follow FDA guidelines for short-term use or failed to monitor for TD. The boxed warning from the FDA states that Reglan should be used for the shortest duration necessary and that the risk of TD increases with cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Reglan exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.